Future Oncology
Volume 20, 2024 - Issue 16: Future Oncology
Open access
2,602
Views
1
CrossRef citations to date
0
Altmetric
Clinical Trial Protocol
Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors
Changhoon Yoo1 Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of KoreaCorrespondence[email protected]
https://orcid.org/0000-0002-1451-8455View further author information
Angela Lamarca2 Department of Medical Oncology, Fundacion Jimenez Diaz University Hospital, 28040 Madrid, SpainView further author information
, Hye Jin Choi3 Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul 03722, Republic of KoreaView further author information
, Arndt Vogel4 Department of Gastroenterology, Hepatology & Endocrinology, Hannover Medical School, 0625 Hannover, Germany;5 Department of Gastroenterology & Hepatology, Toronto General Hospital, Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON, M5G 2C4, CanadaView further author information
, Michael J Pishvaian6 Department of Oncology, John Hopkins University, Washington, DC 20016, USAView further author information
, Lipika Goyal7 Stanford Cancer Center, Palo Alto, CA 94305, USAView further author information
, Makoto Ueno8 Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Kanagawa 241-8515, JapanView further author information
, Angela Märten9 Boehringer Ingelheim International GmbH, 55218 Ingelheim am Rhein, GermanyView further author information
, Michael Teufel10 Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT 0687, USAView further author information
, Lijiang Geng11 Boehringer Ingelheim (China) Investment Co., Shanghai 200040, ChinaView further author information
& Chigusa Morizane12 Department of Hepatobiliary & Pancreatic Oncology, National Cancer Center Hospital, Tokyo 104-0045, JapanView further author information
show all
Pages 1069-1077
|
Received 10 Nov 2023, Accepted 14 Dec 2023, Published online: 12 Jan 2024
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.